Our findings in this study revealed that the levels of circulating CD8+CD38+ T cells, CD8+CD28+ T cells, and NK cells are potential prognostic factors for tumor response and long-term survival in patients with HCC treated with TACE, administered with or without PD-1 inhibitors. The gene discussed is CD38; the disease is hepatocellular carcinoma.